Voyager Therapeutics, Inc. (VYGR)

Every figure this model derived for VYGR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 847,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 116,338,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 125,228,000 AssetsCurrent 2026-06-30
current liabilities 16,685,000 LiabilitiesCurrent 2026-06-30
equity 154,377,000 StockholdersEquity 2026-06-30
ocf -120,572,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 34,459,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 11,902,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up VYGR on one particular measure came for.

RatioValue
cash operating margin-294.45
current ratio7.62
current ratio reported7.51
deferred revenue growth-98.81
dilution pct1.78
fcf margin-352.36
growth cv3.47
operating margin-340.08
owner earnings margin-386.9
revenue growth-19.07
revenue growth per share-20.48
roic-243.38
rule of 40-359.15
sbc pct revenue34.54

What to be careful about

What this model itself distrusts about VYGR's figures. Written by the derivation as it ran, not added afterwards.